vigabatrin Sabril
Selected indexed studies
- Vigabatrin (Sabril) for the Treatment of Refractory Complex Focal Seizures in Adults: Pharmacologic and Clinical Considerations. (Cureus, 2023) [PMID:37927747]
- Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin. (Epilepsy Behav, 2016) [PMID:26807550]
- The ocular side effects of vigabatrin (Sabril): information and guidance for screening. (Eye (Lond), 2008) [PMID:18497834]
_Worker-drafted node — pending editorial review._
Connections
vigabatrin Sabril is a side effect of
Sources
- Vigabatrin (Sabril) for the Treatment of Refractory Complex Focal Seizures in Adults: Pharmacologic and Clinical Considerations. (2023) pubmed
- Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin. (2016) pubmed
- The ocular side effects of vigabatrin (Sabril): information and guidance for screening. (2008) pubmed
- Vigabatrin (Sabril) for epilepsy. (2010) pubmed
- Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. (2009) pubmed
- Multicentre clinical evaluation of vigabatrin (Sabril) in mild to moderate partial epilepsies. French Neurologists Sabril Study Group. (1997) pubmed
- The potential for vigabatrin-induced intramyelinic edema in humans. (2000) pubmed
- Screening for vigabatrin (Sabril ®) retinal toxicity in children. (2011) pubmed
- Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry. (2016) pubmed
- Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. (1995) pubmed